Cardiotoxicity of the BCR-ABL1 tyrosine kinase inhibitors: Emphasis on ponatinib.
Cardio-oncology
Cardiotoxicity
Ponatinib
Tyrosine kinase inhibitor
Journal
International journal of cardiology
ISSN: 1874-1754
Titre abrégé: Int J Cardiol
Pays: Netherlands
ID NLM: 8200291
Informations de publication
Date de publication:
01 10 2020
01 10 2020
Historique:
received:
21
02
2020
revised:
20
05
2020
accepted:
24
05
2020
pubmed:
30
5
2020
medline:
15
5
2021
entrez:
30
5
2020
Statut:
ppublish
Résumé
The advent of tyrosine kinase inhibitors (TKIs) targeted therapy revolutionized the treatment of chronic myeloid leukemia (CML) patients. However, cardiotoxicity associated with these targeted therapies puts the cancer survivors at higher risk. Ponatinib is a third-generation TKI for the treatment of CML patients having gatekeeper mutation T315I, which is resistant to the first and second generation of TKIs, namely, imatinib, nilotinib, dasatinib, and bosutinib. Multiple unbiased screening from our lab and others have identified ponatinib as most cardiotoxic FDA approved TKI among the entire FDA approved TKI family (total 50+). Indeed, ponatinib is the only treatment option for CML patients with T315I mutation. This review focusses on the cardiovascular risks and mechanism/s associated with CML TKIs with a particular focus on ponatinib cardiotoxicity. We have summarized our recent findings with transgenic zebrafish line harboring BNP luciferase activity to demonstrate the cardiotoxic potential of ponatinib. Additionally, we will review the recent discoveries reported by our and other laboratories that ponatinib primarily exerts its cardiotoxicity via an off-target effect on cardiomyocyte prosurvival signaling pathways, AKT and ERK. Finally, we will shed light on future directions for minimizing the adverse sequelae associated with CML-TKIs.
Identifiants
pubmed: 32470534
pii: S0167-5273(20)30723-3
doi: 10.1016/j.ijcard.2020.05.077
pmc: PMC8095092
mid: NIHMS1691486
pii:
doi:
Substances chimiques
Antineoplastic Agents
0
Imidazoles
0
Protein Kinase Inhibitors
0
Pyridazines
0
ponatinib
4340891KFS
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
214-221Subventions
Organisme : NHLBI NIH HHS
ID : R01 HL119234
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL133290
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL143074
Pays : United States
Informations de copyright
Copyright © 2020 Elsevier B.V. All rights reserved.
Références
N Engl J Med. 2006 Dec 7;355(23):2408-17
pubmed: 17151364
Nat Med. 2006 Aug;12(8):908-16
pubmed: 16862153
Biomed Res Int. 2014;2014:637059
pubmed: 25025064
Protein Cell. 2019 Mar;10(3):161-177
pubmed: 29667003
Cancer Chemother Pharmacol. 2013 Jun;71(6):1599-607
pubmed: 23609479
Cancer Biol Ther. 2016;17(1):65-78
pubmed: 26574622
Mol Cancer Ther. 2012 Mar;11(3):690-9
pubmed: 22238366
Invest New Drugs. 2016 Dec;34(6):685-692
pubmed: 27586230
Am J Hematol. 2011 Jul;86(7):610-1
pubmed: 21630307
Nature. 2010 Jan 28;463(7280):501-6
pubmed: 20072125
Blood. 2019 Apr 4;133(14):1597-1606
pubmed: 30692122
Clin Cancer Res. 2006 Dec 15;12(24):7374-9
pubmed: 17189410
Leukemia. 2015 Sep;29(9):1823-31
pubmed: 26088952
Science. 2001 Aug 3;293(5531):876-80
pubmed: 11423618
Leukemia. 2009 Jun;23(6):1054-61
pubmed: 19282833
J Clin Oncol. 2015 Dec 10;33(35):4210-8
pubmed: 26371140
Science. 2004 Jul 16;305(5682):399-401
pubmed: 15256671
Biologics. 2014 Oct 20;8:243-54
pubmed: 25349473
Drug Discov Today. 2013 Oct;18(19-20):992-1000
pubmed: 23769978
Cancer Cell. 2005 Feb;7(2):129-41
pubmed: 15710326
Fundam Clin Pharmacol. 2015 Apr;29(2):204-8
pubmed: 25619238
Cancer Cell. 2009 Nov 6;16(5):401-12
pubmed: 19878872
Science. 1986 Jul 11;233(4760):212-4
pubmed: 3460176
Cancer Res. 2012 Oct 1;72(19):4890-5
pubmed: 23002203
Mol Cell Endocrinol. 2013 Sep 5;377(1-2):1-6
pubmed: 23811235
Cancer Res. 2008 Apr 15;68(8):2576-80
pubmed: 18413724
Br J Haematol. 2012 May;157(4):483-92
pubmed: 22409268
N Engl J Med. 2012 Nov 29;367(22):2075-88
pubmed: 23190221
J Clin Med. 2020 Mar 18;9(3):
pubmed: 32197359
PLoS One. 2013 Oct 04;8(10):e76551
pubmed: 24124571
Acta Haematol. 2020;143(3):217-231
pubmed: 31590170
Leuk Lymphoma. 2017 Jun;58(6):1455-1467
pubmed: 27733071
Exp Hematol. 2014 Apr;42(4):282-293.e4
pubmed: 24407160
Mol Cancer. 2014 Jan 28;13:17
pubmed: 24472312
Cancer Chemother Pharmacol. 2008 Mar;61(3):365-76
pubmed: 17429625
J Thorac Oncol. 2014 Sep;9(9):1316-23
pubmed: 25122427
Oncotarget. 2017 Jan 24;8(4):5874-5884
pubmed: 27564113
Haematologica. 2013 Jan;98(1):103-6
pubmed: 22875613
Blood. 2018 Jul 26;132(4):393-404
pubmed: 29567798
Cancer Control. 2009 Apr;16(2):122-31
pubmed: 19337198
CA Cancer J Clin. 2015 Jan-Feb;65(1):5-29
pubmed: 25559415
Int J Cardiol. 2019 Aug 1;288:124-127
pubmed: 31029498
Am J Hematol. 2011 Jul;86(7):533-9
pubmed: 21538470
Mol Cancer Ther. 2011 Jun;10(6):1028-35
pubmed: 21482694
Cancer. 2010 Jan 1;116(1):184-92
pubmed: 19885836
Sci Transl Med. 2017 Feb 15;9(377):
pubmed: 28202772
Eur Heart J. 2016 Sep 21;37(36):2768-2801
pubmed: 27567406
Leuk Res. 2017 Aug;59:47-54
pubmed: 28549238
J Exp Clin Cancer Res. 2017 Jan 9;36(1):8
pubmed: 28069043
Blood. 2009 Dec 3;114(24):4944-53
pubmed: 19779040
Oncol Rep. 2013 Jun;29(6):2181-90
pubmed: 23563700
Hematol Oncol. 2019 Aug;37(3):296-302
pubmed: 30892724
Blood. 2011 Aug 4;118(5):1208-15
pubmed: 21562040
J Hematol Oncol. 2017 Nov 13;10(1):173
pubmed: 29132397
Blood Adv. 2020 Feb 11;4(3):530-538
pubmed: 32045474
Heart Fail Rev. 2020 May;25(3):447-456
pubmed: 32026180
Leukemia. 2006 Jun;20(6):1061-6
pubmed: 16642048
Lancet Oncol. 2016 May;17(5):612-21
pubmed: 27083332
Clin Cancer Res. 2018 Apr 15;24(8):1932-1943
pubmed: 29440177
Cell Rep. 2016 Oct 25;17(5):1265-1275
pubmed: 27783942
Ann Hematol. 2017 Apr;96(4):549-558
pubmed: 27686083
Leukemia. 2013 Jan;27(1):32-40
pubmed: 22781593
PLoS One. 2013;8(1):e53233
pubmed: 23365636
N Engl J Med. 2003 Mar 13;348(11):994-1004
pubmed: 12637609
N Engl J Med. 2013 Nov 7;369(19):1783-96
pubmed: 24180494
Front Cardiovasc Med. 2018 Jun 12;5:55
pubmed: 29946549
Clin Lymphoma Myeloma Leuk. 2012 Oct;12(5):337-40
pubmed: 22633167
Syst Rev. 2018 Jul 31;7(1):112
pubmed: 30064502
Cancer Chemother Pharmacol. 2013 May;71(5):1315-23
pubmed: 23468082
Stem Cell Res Ther. 2013 Dec 24;4(6):150
pubmed: 24476344
Leukemia. 2016 Aug;30(8):1648-71
pubmed: 27121688
Thromb Haemost. 2019 Jul;119(7):1112-1123
pubmed: 31079415
Blood. 2007 Aug 15;110(4):1233-7
pubmed: 17449798
Hum Mol Genet. 2017 May 15;26(10):1801-1810
pubmed: 28334876
Toxicol Sci. 2015 Jan;143(1):147-55
pubmed: 25304212
Blood Adv. 2019 Mar 26;3(6):851-861
pubmed: 30885996
Blood. 2007 Oct 1;110(7):2242-9
pubmed: 17496200
Clin Cancer Res. 2014 Nov 15;20(22):5745-5755
pubmed: 25239608
Cancer Chemother Pharmacol. 2013 Jan;71(1):123-32
pubmed: 23053269
Cardiovasc Res. 2012 Mar 1;93(3):463-70
pubmed: 22198505
CA Cancer J Clin. 2017 Jan;67(1):7-30
pubmed: 28055103
Oncotarget. 2017 May 9;8(19):31666-31681
pubmed: 28427224
J Clin Endocrinol Metab. 2013 May;98(5):E811-9
pubmed: 23526464
Nature. 1985 Jun 13-19;315(6020):550-4
pubmed: 2989692
Cardiovasc Res. 2019 Apr 15;115(5):966-977
pubmed: 30629146
Chemotherapy. 2019;64(4):205-209
pubmed: 31825920
Ther Adv Hematol. 2019 Mar 01;10:2040620719826444
pubmed: 30854182